BioPlus Acquisition Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on BioPlus Acquisition's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How BioPlus Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | 6 | 2 | 0 |
| 31 Mar 23 | 0 | 5 | 1 | 0 |
| 31 Dec 22 | 0 | 2 | 1 | 0 |
| 30 Sep 22 | 0 | 0 | 1 | 0 |
| 30 Jun 22 | 0 | 0 | 1 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
Quality Earnings: BIOS.U has high quality earnings.
Growing Profit Margin: BIOS.U became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if BIOS.U's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare BIOS.U's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: BIOS.U has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (2.4%).
Return on Equity
High ROE: BIOS.U's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.